MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 564446 | Name: MT63-78
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MT63-78 is a direct activator of AMPK, and an inhibitor of prostate cancer growth by blocking lipogenesis.

Chemical Structure

MT63-78
MT63-78
CAS#1179347-65-9

Theoretical Analysis

MedKoo Cat#: 564446

Name: MT63-78

CAS#: 1179347-65-9

Chemical Formula: C21H14N2O2

Exact Mass: 326.1055

Molecular Weight: 326.36

Elemental Analysis: C, 77.29; H, 4.32; N, 8.58; O, 9.80

Price and Availability

Size Price Availability Quantity
25mg USD 550.00 2 Weeks
50mg USD 950.00 2 Weeks
100mg USD 1,650.00 2 Weeks
1g USD 4,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MT63-78; MT 63-78; MT-63-78; MT6378; MT 6378; MT-6378;
IUPAC/Chemical Name
5-(2',6'-Dihydroxy-[1,1'-biphenyl]-4-yl)-1H-indole-3-carbonitrile
InChi Key
IGSYZPLXAFVMKY-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H14N2O2/c22-11-16-12-23-18-9-8-15(10-17(16)18)13-4-6-14(7-5-13)21-19(24)2-1-3-20(21)25/h1-10,12,23-25H
SMILES Code
N#CC1=CNC2=C1C=C(C3=CC=C(C4=C(O)C=CC=C4O)C=C3)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
MT 63-78 is a specific and potent direct AMPK activator with an EC50 of 25 μM.
In vitro activity:
A small molecule screening was performed and identified MT 63-78, a specific and potent direct AMPK activator. Here, this study shows that direct activation of AMPK inhibits PCa cell growth in androgen sensitive and castration resistant PCa (CRPC) models, induces mitotic arrest, and apoptosis. Reference: EMBO Mol Med. 2014 Apr;6(4):519-38. https://pubmed.ncbi.nlm.nih.gov/24497570/
In vivo activity:
In vivo, AMPK activation is sufficient to reduce PCa growth in mice, whereas the allelic loss of its catalytic subunits fosters PCa development. Importantly, despite mTORC1 blockade, the suppression of de novo lipogenesis is the underpinning mechanism responsible for AMPK-mediated PCa growth inhibition, suggesting AMPK as a therapeutic target especially for lipogenesis-driven PCas. Reference: EMBO Mol Med. 2014 Apr;6(4):519-38. https://pubmed.ncbi.nlm.nih.gov/24497570/
Solvent mg/mL mM
Solubility
DMSO 125.0 383.02
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 326.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, Liu H, Scaglia N, Priolo C, Sicinska E, Mahmood U, Signoretti S, Birnberg N, Loda M. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med. 2014 Apr;6(4):519-38. doi: 10.1002/emmm.201302734. Epub 2014 Feb 4. Erratum in: EMBO Mol Med. 2014 Oct;6(10):1357. PMID: 24497570; PMCID: PMC3992078.
In vitro protocol:
Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, Liu H, Scaglia N, Priolo C, Sicinska E, Mahmood U, Signoretti S, Birnberg N, Loda M. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med. 2014 Apr;6(4):519-38. doi: 10.1002/emmm.201302734. Epub 2014 Feb 4. Erratum in: EMBO Mol Med. 2014 Oct;6(10):1357. PMID: 24497570; PMCID: PMC3992078.
In vivo protocol:
Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, Liu H, Scaglia N, Priolo C, Sicinska E, Mahmood U, Signoretti S, Birnberg N, Loda M. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med. 2014 Apr;6(4):519-38. doi: 10.1002/emmm.201302734. Epub 2014 Feb 4. Erratum in: EMBO Mol Med. 2014 Oct;6(10):1357. PMID: 24497570; PMCID: PMC3992078.
Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, Liu H, Scaglia N, Priolo C, Sicinska E, Mahmood U, Signoretti S, Birnberg N, Loda M. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med. 2014 Apr;6(4):519-38. doi: 10.1002/emmm.201302734. Epub 2014 Feb 4. Erratum in: EMBO Mol Med. 2014 Oct;6(10):1357. PMID: 24497570; PMCID: PMC3992078.